Medical Devices

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

STAAR Surgical stockholders rejected a lucrative Alcon merger, betting on the standalone potential of their EVO ICL lenses despite recent financial headwinds.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.

In a strategic move to become a one-stop shop for medical implants, Resonetics acquires pulse generator tech, targeting the booming neuromodulation and BCI markets.

Health Canada greenlights an 8-week pill for acute HCV, a move experts say is a game-changer in the race to eradicate the virus by 2030.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

Cosmos Health's subsidiary will manufacture the advanced generic pain reliever PathMuscle, securing a major contract and enhancing its European footprint.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

With promising 3-year vision data and a manufacturing breakthrough, Lineage is pioneering 'off-the-shelf' cell therapies for blindness, diabetes, and more.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

A global RFA leader unveils a new identity, reflecting a strategic shift from pure engineering to a focus on the patient's quality of life.

With key trials in brain and prostate cancer, Curasight heads to a top investor conference to showcase its dual-action theranostic technology.

The eye health giant has refinanced a massive $2.8B in loans, extending debt maturity and cutting interest costs to bolster its long-term strategy.

RxSight will showcase its unique post-surgery adjustable lens at J.P. Morgan, facing investor questions on growth in a competitive ophthalmology market.